Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine.
Maillard or browning reactions lead to formation of advanced glycation end products (AGEs) on protein and contribute to the increase in chemical modification of proteins during aging and in diabetes. AGE inhibitors such as aminoguanidine and pyridoxamine (PM) have proven effective in animal model and clinical studies as inhibitors of AGE formation and development of diabetic complications. We report here that PM also inhibits the chemical modification of proteins during lipid peroxidation (lipoxidation) reactions in vitro, and we show that it traps reactive intermediates formed during lipid peroxidation. In reactions of arachidonate with the model protein RNase, PM prevented modification of lysine residues and formation of the advanced lipoxidation end products (ALEs) N(epsilon)-(carboxymethyl)lysine, N(epsilon)-(carboxyethyl)lysine, malondialdehyde-lysine, and 4-hydroxynonenal-lysine. PM also inhibited lysine modification and formation of ALEs during copper-catalyzed oxidation of low density lipoprotein. Hexanoic acid amide and nonanedioic acid monoamide derivatives of PM were identified as major products formed during oxidation of linoleic acid in the presence of PM. We propose a mechanism for formation of these products from the 9- and 13-oxo-decadienoic acid intermediates formed during peroxidation of linoleic acid. PM, as a potent inhibitor of both AGE and ALE formation, may prove useful for limiting the increased chemical modification of tissue proteins and associated pathology in aging and chronic diseases, including both diabetes and atherosclerosis.
Onorato
J M
JM
Department of Chemistry, University of South Carolina, Columbia, South Carolina 29208, USA.
Jenkins
A J
AJ
Thorpe
S R
SR
Baynes
J W
JW
D016718:Arachidonic Acid / Q000378:metabolism*; D003300:Copper / Q000737:chemistry; D005230:Fatty Acids, Nonesterified / Q000737:chemistry*; D005231:Fatty Acids, Unsaturated / Q000737:chemistry*; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors*; D006801:Humans; D007700:Kinetics; D015227:Lipid Peroxidation / Q000187:drug effects*; D008077:Lipoproteins, LDL / Q000187:drug effects / Q000378:metabolism; D008239:Lysine / Q000378:metabolism; D011733:Pyridoxamine / Q000031:analogs & derivatives / Q000737:chemistry* / Q000494:pharmacology*; D012260:Ribonucleases / Q000378:metabolism*
D005230:Fatty Acids, Nonesterified; D005231:Fatty Acids, Unsaturated; D017127:Glycation End Products, Advanced; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein; D016718:Arachidonic Acid; D011733:Pyridoxamine; D003300:Copper; D012260:Ribonucleases; D008239:Lysine